The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@nolondon1234 The lesson for BCN investors (well, any investors) is from Bloomberg columnist Matt Levin, who writes: All of these companies, in their disclosures to foreign investors, include risk factors about how the legal status of their VIE structures is uncertain and how the Chinese government might decide that they are in violation of the law and impose all sorts of remedies, like “confiscating any of our income that they deem to be obtained through illegal operations” or “revoking the business and operating licenses of our PRC subsidiaries or consolidated affiliated entities.” In a sense there is nothing surprising here; the boom in foreign investment in Chinese tech companies has been entirely a creature of regulatory grace that might end at any time. People got used to the grace, though. Now it might be ending.
The complaints about Ganfeng in 2021 have roots in what BCN allowed Ganfeng to do years ago. It was no secret, though. Investors simply chose to ignore the obvious: When Ganfeng became the only major that might take over a semi-captive junior, how much did that devalue the property? Possession of money does not guarantee possession of reason. Emotions run rampant, and the country with more EV's will do what it takes to keep building them.
@Bonkers0801 I sold some of my BCN shares today for 64p. The price of the US OTC version reached 88 cents. Probably should have sold all of them, but then I wouldn't have as much fun watching the tragicomedy.
Have you been following the whole debacle with chinese tutoring companies lately?
Definite sign of things to come imo.. taking foreign capital until they don't want it anymore.. then run.
Holding firm, but a very boring share right now , this share will do nothing right up until the offer is made or pulled. The market will never take this above 67.5p now.
Makes you wonder where we would of been with no potential offer on the tabe and the rns with the operational update , not saying we would be higher but I have seen some lithium stocks do crazy things last few weeks.
Secker has absolutly killed this share and the sooner my 67.5p a share comes the better , I'm lucky my sheer arrogance to refuse to sell this share until offer is here is stronger then my patience , because my patience is wearing thin.
One of my more exciting and long term shares on my portfolio has turned into the most frustrating.